XPENG-MOTORS
14.3.2022 14:34:04 CET | Business Wire | Press release
XPENG, a leading smart electric vehicle and mobility technology company, today announced that it has joined three major European automobile associations, the European Association for Electromobility (AVERE), Royal RAI Vereniging / RAI Association (RAI) and BIL Sweden, underlining the company's long-term commitment to developing the smart and greener mobility ecosystem in Europe.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220314005486/en/
Leveraging its strong expertise in innovative technology and sustainable mobility, XPENG will bring valuable insights in the smart EV sector, contributing to the development and implementation of the European Commission's Sustainable and Smart Mobility Strategy.
“We appreciate the extraordinary commitment that Europe has made to carbon neutrality and sustainable mobility,” said Leon He, Vice President of XPENG. “Our vision is to transform future mobility with technology. By consolidating our industry connections and actively engaging with the European automobile sector, we hope to accelerate the development of electrification, digitization and automation technologies for the auto sector. XPENG will continue to invest in innovations and is excited to work together with automobile stakeholders in Europe to achieve our shared vision: building a sustainable mobility ecosystem for the future.”
AVERE is the leading European association that promotes electromobility and sustainable transport across Europe. It represents and advocates for electromobility on behalf of the industry, academia, and EV users at both EU and national levels.
“We at AVERE are delighted to welcome XPENG as a member as it continues to develop and invest in Europe,” said Philippe Vangeel, Secretary-General of AVERE. “We look forward to engaging and working together with XPENG in shaping the future of smart and sustainable mobility.”
The Royal RAI Vereniging represents the interests of enterprises in the mobility sector in the Netherlands, and plays an active role in facilitating the production and sales of vehicles and parts for its 700 members, who together supply all forms of road transportation.
Steven van Eijck, Chairman of the Royal RAI Vereniging, commented: “We are very happy to welcome XPENG as our new member. XPENG plays an important role in the rapidly growing market for electric mobility, particularly passenger cars in the world. This is essential as we transition towards a zero-emission mobility system to meet our environmental and climate goals. The Dutch passenger car market is leading the initiatives in Europe when it comes to electrification. It acts as a gateway to the European passenger car market and is therefore attractive for newcomers.”
BIL Sweden is the Swedish industry organization for manufacturers and importers of cars, trucks and buses. The member companies together account for around 97 percent of new car sales in Sweden. The organization acknowledges that vehicles are a key player in the sustainable society focused on climate and environmental issues, safety and mobility development. BIL Sweden's vision for the year 2030: building long-term sustainable mobility and transportation solutions.
"BIL Sweden aims to work for a society that achieves its climate goals through developing long-term carbon-neutral strategies that promote energy efficiency and renewable energy vehicles. We believe that fossil fuels can be gradually phased out and replaced with renewable fuels and electrification as we improve energy efficiency. We are confident that companies like XPENG, which are focused on electric power, technology and innovation, are well positioned to contribute to this development. I am really looking forward to having them in BIL Sweden," said Mattias Bergman, CEO of BIL Sweden.
Earlier, XPENG announced the opening of its first European Experience Stores in Sweden and the Netherlands, and its partnership with Bilia and Emil Frey Nederland NV to build a first-class distribution, sales and service network in Sweden and the Netherlands, respectively.
The company is committed to Europe’s carbon-neutral initiatives and is dedicated to building intelligent, sustainable and people-first mobility solutions. XPENG differentiates itself with its full-stack in-house Advanced Driver Assistance System (ADAS) technologies and in-car intelligent operating system, as well as core vehicle systems including powertrain and electrification/electronic architecture, providing superior and safe mobility experience a growing base of customers.
About XPENG
https://heyxpeng.com/
About AVERE
https://www.avere.org/what-is-avere/
About Royal RAI Vereniging / RAI Association
https://www.raivereniging.nl/automotiveindustrynl/over-ons
About BIL Sweden
https://www.bilsweden.se/
View source version on businesswire.com: https://www.businesswire.com/news/home/20220314005486/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom